Healthcare Global Enterprises Analysis

dividend

Pros

Cons

• No need to calculate the sustainability of HealthCare Global Enterprises's dividends in 3 years as they are not expected to pay a notable one for India.
• Unable to evaluate HealthCare Global Enterprises's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
• Unable to evaluate HealthCare Global Enterprises's dividend against the top 25% market benchmark as the company has not reported any payouts.

future

Pros

• Cash flow for HealthCare Global Enterprises is expected to increase by more than 50% in 2 years time.
• HealthCare Global Enterprises's revenue growth is expected to exceed the India market average.

Cons

• HealthCare Global Enterprises is not considered high growth as it is expected to be loss making for the next 1-3 years.
• Unable to compare HealthCare Global Enterprises's earnings growth to the India market average as it is expected to be loss making during the next 1-3 years.
• Unable to compare HealthCare Global Enterprises's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
• HealthCare Global Enterprises is expected to be loss making next year.
• HealthCare Global Enterprises's is expected to be loss making in 2 years.
• Unable to establish if HealthCare Global Enterprises will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
• HealthCare Global Enterprises performance (ROE) can't be compared to the IN Healthcare industry due to having negative earnings in 3 years.
• HealthCare Global Enterprises performance (ROE) is expected to still be negative in 3 years.
• HealthCare Global Enterprises's revenue is expected to increase but not above the 50% threshold in 2 years time.
• HealthCare Global Enterprises's revenue is expected to grow by 12.2% yearly, however this is not considered high growth (20% yearly).

health

Pros

Cons

• HealthCare Global Enterprises's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
• Debt is not well covered by operating cash flow (16.8%, less than 20% of total debt).
• Debt is not covered by short term assets, assets are 0.5x debt.
• HealthCare Global Enterprises's long term commitments exceed its cash and other short term assets.
• The level of debt compared to net worth has increased over the past 5 years (90% vs 117.5% today).
• HealthCare Global Enterprises is making a loss, therefore interest payments are not well covered by earnings.
• HealthCare Global Enterprises's level of debt (117.5%) compared to net worth is high (greater than 40%).
• High level of physical assets or inventory.

management

Pros

• The tenure for the HealthCare Global Enterprises board of directors is about average.
• The average tenure for the HealthCare Global Enterprises management team is over 5 years, this suggests they are a seasoned and experienced team.

Cons

• B. S.'s remuneration is higher than average for companies of similar size in India.
• B. S.'s compensation has increased whilst company is loss making.

misc

Pros

Cons

• HealthCare Global Enterprises has significant price volatility in the past 3 months.

past

Pros

Cons

• Unable to compare HealthCare Global Enterprises's 1-year earnings growth to the 5-year average as it is not currently profitable.
• HealthCare Global Enterprises does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
• HealthCare Global Enterprises used its assets less efficiently than the IN Healthcare industry average last year based on Return on Assets.
• It is difficult to establish if HealthCare Global Enterprises improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
• It is difficult to establish if HealthCare Global Enterprises has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
• Unable to compare HealthCare Global Enterprises's 1-year growth to the IN Healthcare industry average as it is not currently profitable.

value

Pros

• NSEI:HCG is up 28.9% outperforming the Healthcare industry which returned 5.1% over the past month.
• NSEI:HCG is up 28.9% outperforming the market in India which returned 9% over the past month.

Cons

• HealthCare Global Enterprises's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
• HealthCare Global Enterprises's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
• HealthCare Global Enterprises is overvalued based on assets compared to the IN Healthcare industry average.
• HealthCare Global Enterprises is loss making, we can't compare its value to the IN Healthcare industry average.
• HealthCare Global Enterprises is loss making, we can't compare the value of its earnings to the India market.
• HCG underperformed the Healthcare industry which returned 8.5% over the past year.
• HCG underperformed the Market in India which returned -14.8% over the past year.